ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1120

Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra
Abstract Number: 1121

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
Abstract Number: 1122

Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management
Abstract Number: 1123

Serological Elevation of IgG4: Clinical Correlation and Differential Diagnosis
Abstract Number: 1124

Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
Abstract Number: 1125

Non-Classical Complications of Adult-Onset Still’s Disease: A Multicenter Spanish Study
Abstract Number: 1126

The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery
Abstract Number: 1127

Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample
Abstract Number: 1128

A Meta-Analysis of Statin Efficacy in Controlling Disease Activity in Psoriasis
Abstract Number: 1129

Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever
Abstract Number: 1130

Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Abstract Number: 1131

Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
Abstract Number: 1132

Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy
Abstract Number: 1133

Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators
Abstract Number: 1134

First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].